ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

CancerCare Manitoba is encouraging more Manitobans to take part in routine colorectal cancer screening, particularly in ...

They told me it was effective, and I knew mailing a Cologuard box back would be pretty dang easy.” Cologuard — a simple way ...

The nationwide rollout, which Labcorp disclosed Monday, comes weeks after the Centers for Medicare and Medicaid Services approved coverage for ColoSense, and the American Cancer Society named the test ...

Earlier this week, Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare ...

Karin Gilkison, MD, Gastroenterology, is now seeing patients Chaska and Waconia. Dr. Gilkison is board-certified in internal medicine and gastroenterology, a Fellow of the American College of Gastroen ...

InfuSystem (INFU) stock: buy case on 11.6% FCF yield, margin gains, low EV/EBITDA, and ERP efficiencies—plus key risks. See ...

Bryce Ramsey of Madison, Mississippi, was 33 when she was diagnosed with colorectal cancer. Upon noticing blood in her stool, ...

Mediaplanet today announces the launch of its latest Digestive Health campaign, distributed nationwide within USA TODAY and ...

A new blood test for colorectal cancer screening is being implemented in Alabama to improve early detection and reduce deaths from the disease.

While colorectal cancer polyps often have no symptoms—especially in the early stages—there are some warning signs to be on the lookout for...plus one common myth about polyps. The post 8 Symptoms of ...

Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable. Read more on ...